# Fathom Therapeutics

> New York preclinical drug-discovery company combining protein-motion simulations, quantum chemistry and AI to design small-molecule therapies.

## Why it is interesting

A November 6 Kos Biotechnology Partners release resurfaced Fathom's already-completed $55M May 2026 Series A, which had been publicly reported at $47M in April. The newer investor announcement is not a new $55M round. Fathom's Microcosmos work targets dynamic protein conformations that static-structure drug design can miss.

## Profile

- **Latest funding:** Series A (cumulative; original $47M announced April 27, expanded to $55M by May) — $55M (May 2026)
- **Latest known valuation:** Undisclosed (May 2026)
- **Total disclosed equity funding:** $55M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-09
- **Latest funding investors:** Sutter Hill Ventures, Lilly Ventures, Chemistry, Alexandria Venture Investments, Empire State Development NY Ventures, Kos BioVentures (Kos Biotechnology Partners)

## Key facts

- $47M Series A announced April 27, 2026; updated to $55M total Series A financing in May, not $47M plus $55M.
- November 6, 2026 Kos BioVentures announcement identifies participation in the earlier financing; individual cheque undisclosed.
- Sutter Hill Ventures led; Lilly Ventures, Chemistry, Alexandria Venture Investments, NY Ventures and Kos among disclosed participants.
- Preclinical Microcosmos combines protein dynamics simulations and AI with wet-lab experiments; no disclosed human efficacy outcome.
- 12 discovery partnerships reported in BIO 2026 issuer profile; partner contract economics and valuation undisclosed.

## Funding history

- Series A (cumulative; original $47M announced April 27, expanded to $55M by May) · $55M · May 2026
  Source: https://www.prnewswire.com/news-releases/fathom-therapeutics-appoints-bret-williams-as-chief-scientific-officer-to-translate-microcosmos-insights-into-a-therapeutic-portfolio-302923780.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 9, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/fathom-therapeutics